Qiagen N.V. $QGEN Shares Acquired by Barclays PLC

Barclays PLC increased its stake in shares of Qiagen N.V. (NYSE:QGEN) by 14.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,086,931 shares of the company’s stock after purchasing an additional 135,638 shares during the period. Barclays PLC owned 0.49% of Qiagen worth $48,564,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Atria Investments Inc raised its holdings in shares of Qiagen by 2.9% in the second quarter. Atria Investments Inc now owns 7,674 shares of the company’s stock worth $369,000 after acquiring an additional 218 shares during the last quarter. Johnson Investment Counsel Inc. lifted its holdings in Qiagen by 0.4% in the 3rd quarter. Johnson Investment Counsel Inc. now owns 57,359 shares of the company’s stock valued at $2,563,000 after purchasing an additional 240 shares in the last quarter. Bessemer Group Inc. boosted its stake in shares of Qiagen by 0.5% during the 3rd quarter. Bessemer Group Inc. now owns 51,780 shares of the company’s stock worth $2,288,000 after purchasing an additional 262 shares during the last quarter. Covestor Ltd boosted its stake in shares of Qiagen by 13.6% during the 3rd quarter. Covestor Ltd now owns 3,007 shares of the company’s stock worth $134,000 after purchasing an additional 361 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in shares of Qiagen by 4.5% during the second quarter. PNC Financial Services Group Inc. now owns 9,672 shares of the company’s stock worth $465,000 after buying an additional 415 shares in the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft downgraded shares of Qiagen from a “buy” rating to a “hold” rating and upped their price objective for the company from $52.00 to $54.00 in a research note on Thursday, January 22nd. Barclays set a $58.00 price target on Qiagen and gave the company an “overweight” rating in a report on Friday, February 6th. JPMorgan Chase & Co. lifted their price objective on Qiagen from $55.00 to $60.00 and gave the company an “overweight” rating in a research report on Friday, February 6th. Jefferies Financial Group reiterated a “buy” rating and set a $59.00 target price on shares of Qiagen in a research report on Thursday, February 5th. Finally, Citigroup lowered their price target on Qiagen from $55.40 to $55.00 and set a “neutral” rating for the company in a report on Friday, February 6th. Four equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $55.20.

Qiagen Trading Down 2.7%

QGEN stock opened at $43.36 on Tuesday. Qiagen N.V. has a 52 week low of $40.14 and a 52 week high of $57.81. The company has a market cap of $9.16 billion, a price-to-earnings ratio of 21.50, a PEG ratio of 2.17 and a beta of 0.70. The company has a quick ratio of 3.31, a current ratio of 3.90 and a debt-to-equity ratio of 0.44. The business has a fifty day simple moving average of $49.80 and a 200-day simple moving average of $49.11.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Thursday, February 5th. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.61 by $0.01. Qiagen had a net margin of 20.33% and a return on equity of 14.56%. The firm had revenue of $540.42 million for the quarter, compared to analyst estimates of $528.53 million. During the same quarter last year, the firm posted $0.61 earnings per share. Qiagen’s revenue for the quarter was up 3.6% compared to the same quarter last year. On average, equities research analysts expect that Qiagen N.V. will post 2.26 EPS for the current year.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.